For a patient with a history of actinic keratoses, basal‑cell carcinoma, and squamous‑cell carcinoma, what oral nicotinamide regimen (dose, duration, and monitoring) is recommended for skin cancer prevention?

Oral Nicotinamide for Skin Cancer Prevention

For patients with a history of actinic keratoses, basal-cell carcinoma, and squamous-cell carcinoma, oral nicotinamide 500 mg twice daily should be considered, though current AAD guidelines state there is insufficient evidence to make a formal recommendation for BCC chemoprevention, while noting early evidence of benefit for keratinocyte carcinomas in non-immunosuppressed individuals.

The Evidence Landscape

The 2018 AAD guidelines for both BCC and cSCC management acknowledge that "there is early evidence from a small trial that oral nicotinamide may reduce the risk for subsequent keratinocyte carcinoma in nonimmunosuppressed individuals" 1, 2. However, the BCC guidelines specifically assign a "B" strength recommendation with Level I evidence for oral nicotinamide in chemoprevention, while simultaneously stating "there is insufficient evidence to make a recommendation" 1. This apparent contradiction reflects the guideline committee's cautious interpretation of limited data available at the time.

Key Clinical Trial Data

The landmark ONTRAC trial 3 demonstrated that nicotinamide 500 mg twice daily for 12 months resulted in:

• 23% reduction in new non-melanoma skin cancers (95% CI, 4-38%; P=0.02)
• 30% reduction in new squamous-cell carcinomas (95% CI, 0-51%; P=0.05)
• 20% reduction in new basal-cell carcinomas (95% CI, -6 to 39%; P=0.12)
• 11-20% reduction in actinic keratoses at various time points (P<0.001)

Critical limitation: Benefits disappeared after discontinuation, indicating the need for continuous therapy.

Recent Evidence Updates

More recent data shows conflicting results:

• A 2025 retrospective VA study 4 of 33,822 patients found a 14% overall reduction in skin cancer risk and 22% reduction in cSCC, with greatest benefit when initiated after the first skin cancer (54% risk reduction).

• However, two systematic reviews and meta-analyses 5, 6 found no significant association between nicotinamide and reduced NMSC risk when pooling immunocompetent and immunosuppressed patients together (RR 0.82,95% CI 0.61-1.12 for NMSC; RR 0.81 for SCC; RR 0.88 for BCC).

• A 2025 study in solid organ transplant recipients 7 showed significant benefit with mean reduction of 2.19 KCs at one year (P=0.0012), though this represents a different population than your patient.

Recommended Regimen

Dose

Nicotinamide 500 mg orally twice daily (total 1000 mg/day) 3, 8

Duration

• Continuous therapy is required - benefits cease upon discontinuation 3
• The ONTRAC trial demonstrated efficacy over 12 months with no benefit in the 6-month post-intervention period
• Consider this a long-term preventive strategy, not a time-limited course

Monitoring

• No specific laboratory monitoring is required 3
• Adverse events are rare and primarily gastrointestinal (nausea, diarrhea) 3, 5
• The safety profile is excellent with minimal side effects
• Clinical skin examinations should continue every 3-6 months regardless of nicotinamide use 1, 2

Clinical Decision-Making Algorithm

Start nicotinamide if:

1. Patient has ≥2 prior keratinocyte carcinomas (BCC or SCC) in the past 5 years
2. Patient is non-immunosuppressed (evidence strongest in this population)
3. Patient can afford and comply with twice-daily dosing
4. Patient accepts that continuous therapy is needed

Consider NOT starting if:

1. Patient is immunosuppressed (conflicting evidence; may still benefit but less certain) 9, 7
2. Cost is prohibitive without insurance coverage
3. Patient unlikely to maintain long-term adherence

Important Caveats

Divergent Evidence

The evidence base shows significant heterogeneity. While the ONTRAC trial 3 showed clear benefit, subsequent meta-analyses 5, 6 failed to confirm this when pooling diverse populations. The most recent large VA study 4 supports benefit but has been criticized for methodological limitations including immortal time bias and unmeasured confounders 10.

Timing Matters

The VA study 4 suggests greatest benefit when initiated after the first skin cancer (54% risk reduction) rather than after multiple cancers. This argues for early initiation in your patient population.

Not a Substitute for Sun Protection

Nicotinamide is adjunctive therapy only. Patients must continue rigorous sun protection, sun avoidance, broad-spectrum sunscreen use, and regular dermatologic surveillance 1, 2.

What NOT to Use

The same guidelines strongly recommend against the following for chemoprevention in your patient:

• Topical or oral retinoids (tretinoin, retinol, acitretin, isotretinoin) - Grade A recommendation against 1, 2
• Selenium supplementation - Grade A recommendation against 1
• Beta-carotene supplementation - Grade A recommendation against 1

Practical Implementation

Given the mixed evidence but favorable safety profile and potential benefit, a reasonable approach is to offer nicotinamide 500 mg twice daily as optional chemoprevention, emphasizing:

• This is not standard of care but has supportive evidence
• Continuous use is required for benefit
• It does not replace sun protection or surveillance
• Side effects are minimal but primarily gastrointestinal
• Cost may be a barrier (~$30-60/month out-of-pocket)

The strongest evidence supports use in non-immunosuppressed patients with multiple prior keratinocyte carcinomas, particularly when initiated early in their disease course.